Multiple sclerosis therapeutics

Description

Content: ""Book Cover"" ""Half-Title"" ""Title"" ""Copyright"" ""Contents"" ""Contributors"" ""Preface to First Edition"" ""Preface to Second Edition"" ""Acknowledgements"" ""I Introduction"" ""1 Aspects of multiple sclerosis that relate to clinical trial design and treatment "" ""II Clinical trial methodology"" ""2 Measures of neurologic impairment and disability in multiple sclerosis"" ""3 Assessment of neuropsychological function in multiple sclerosis"" ""4 Health-related quality of life assessment in multiple sclerosis"" ""5 Magnetic resonance imaging in multiple sclerosis: an overview""""6 Measures of gadolinium enhancement in multiple sclerosis "" ""7 Measures of magnetization transfer in multiple sclerosis"" ""8 Measures of T1 and T2 relaxation in multiple sclerosis"" ""9 Measurement of central nervous system atrophy"" ""10 Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy in multiple sclerosis"" ""11 Functional imaging in multiple sclerosis"" ""12 Use of cost analyses to improve understanding of the therapeutic trade-offs for multiple sclerosis"" ""13 Ethical considerations in multiple sclerosis clinical trials""""14 The process of drug development and approval in the USA, the European Union, and Canada"" ""15 Sponsors, monitoring committees and investigators: the investigator�s perspective"" ""16 Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials"" ""17 The failed clinical trial in multiple sclerosis"" ""18 The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy""""19 Emerging concepts of pathogenesis: relationship to therapies for multiple sclerosis"" ""III Clinical trials of disease-modifying therapy"" ""33 Complementary and alternative treatments in multiple sclerosis"" ""32 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis"" ""31 Combination therapies in multiple sclerosis"" ""30 Emerging disease-modifying therapies for multiple sclerosis"" ""29 Treatment of multiple sclerosis by hematopoietic stem cell transplantation""""28 Cyclophosphamide treatment of multiple sclerosis"" ""27 Treatment of multiple sclerosis with methylprednisolone"" ""26 Therapeutic plasma exchange for multiple sclerosis"" ""25 Intravenous immunoglobulin to treat multiple sclerosis"" ""24 Use of mitoxantrone to treat multiple sclerosis"" ""23 Glatiramer acetate as therapy for multiple sclerosis"" ""22 Biological responses to type I interferons: relationship to therapeutic effects in multiple sclerosis""